Join
Live feed
·
INSIDERFilingvia Quantisnow
Fusion Pharmaceuticals Inc. logo

SEC Form 4: Valliant John sold $225,654 worth of shares (32,849 units at $6.87) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 328,130 units

ByQuantisnow·Wall Street's wire, on your screen.
FUSN· Fusion Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FUSN (Fusion Pharmaceuticals Inc.) and more on Quantisnow.